SPRO Spero Therapeutics, Inc.

$2.27 -0.66%

Healthcare · Pharmaceutical Preparations

Spero Therapeutics, Inc. (SPRO) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $132 million. Shares last traded at $2.27, 29.2% below their 52-week high. Over the past year the stock is down 21.8%. SPRO trades at a price-to-earnings ratio of 15.37, below the Pharmaceutical Preparations median of 16.82. Net profit margin is 68.1%, above the peer median of -0.1%. Revenue grew 3292.5% year over year.

Market Cap

$132M

Shares Out

57.9M

EPS (TTM)

$-1.07

P/E Ratio

15.37

P/S Ratio

10.47

P/B Ratio

2.49

Dividend / Share

—

Dividend Yield

—

52-Week High

$3.21

52-Week Low

$1.80

Volume

165,718

Avg Vol (3m)

51,030.111

Performance

-15.58%

-11.82%

-7.71%

-0.44%

YTD

-3.19%

-21.82%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

36.62

SMA (50)

$2.69

SMA (200)

$2.40

Price vs SMA50

-15.31%

Price vs SMA200

-5.23%

ATR (14)

$0.25

Financials

Revenue

$13M

Net Income

$9M

Gross Margin

—

Operating Margin

50.2%

Net Margin

68.1%

Return on Equity

16.2%

Return on Assets

14.5%

Current Ratio

10.50

Debt / Equity

0.11

Revenue Growth (YoY)

+3292.5%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

Period	EPS (diluted)	Reported
Q1 2026	$-0.13	2026-05-13
FY 2025	$0.15	2026-03-26
Q3 2025	$-0.41	2025-11-13
Q2 2025	$-0.28	2025-08-12
Q1 2026	$-0.25	2026-05-13
FY 2025	$-1.27	2026-03-26

Full earnings history →

Pharmaceutical Preparations peers

SPRO vs 14 industry peers (Pharmaceutical Preparations), by market cap.

P/E vs peers

15.37 / 16.82 med

-9% discount

P/S vs peers

10.47 / 3.54 med

+196% premium

Net margin vs peers

68.1% / -0.1% med

above median

1–14 of 14


LLY	Lilly (Eli)	$1.04T	50.16	15.88	31.7%	-1.17%
JNJ	Johnson & Johnson	$549.8B	20.51	5.84	28.5%	-2.42%
ONC	Beone Medicines Ltd.	$390.6B	1361.26	73.10	5.4%	+2.83%
ABBV	AbbVie	$382.5B	90.51	6.25	6.9%	-2.16%
MRK	Merck	$281.6B	15.43	4.33	28.1%	-1.30%
ABT	Abbott Laboratories	$154.3B	23.65	3.48	14.7%	+0.09%
PFE	Pfizer	$143.7B	18.50	2.30	12.4%	-2.89%
VRTX	Vertex Pharmaceuticals	$114.6B	28.99	9.55	32.9%	-1.63%
BMY	Bristol Myers Squibb	$110.3B	15.63	2.29	14.6%	-2.35%
REGN	Regeneron Pharmaceuticals	$63.4B	14.08	4.42	31.4%	+0.38%
ALNY	Alnylam Pharmaceuticals	$36.9B	117.57	9.93	8.4%	-1.66%
TEVA	Teva Pharmaceutical Industries Ltd	$36.6B	25.98	2.12	8.2%	-3.33%
ZTS	Zoetis	$33.1B	12.37	3.49	28.2%	+2.09%
RPRX	Royalty Pharma Plc	$23.1B	30.02	9.73	32.4%	-1.30%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.